commercial-scale

NSW will be at the forefront of innovative health treatments under a $270 million investment in biomedical research, supporting the creation of two new facilities – the Sydney Biomedical Accelerator Complex in Camperdown and the Viral Vector manufacturing facility at Westmead.

NSW will leverage its cell and gene therapy expertise to establish Australia’s first commercial-scale viral vector manufacturing facility at Westmead.